BIOTRONIK Announces Collaboration with AliveCor As First In A Series of Strategic Partnerships to Disrupt Cardiac Digital Health With AI-Enabled Solutions
BIOTRONIK announced today its partnership with AliveCor, a leading innovator in FDA-cleared personal electrocardiogram (ECG) technology and services. This partnership will combine the strengths of BIOTRONIK’s BIOMONITOR Injectable Cardiac Monitor (designed with industry-leading 95.1% p-wave visibility1 across all cardiac cycles and 5.5 year longevity) with AliveCor’s AI-enabled, clinically validated, medical-grade KardiaMobile 6L and KardiaMobile Card ECG technology. Through this pilot collaboration, healthcare providers will be able to access clinically relevant heart rhythm analyses and actionable reports to monitor at-risk patients; identify underlying arrhythmias, including atrial fibrillation (AF); and assess means to drive improvements to patient care and clinical outcomes.
Up to 25% of stroke patients present with AF2, the most common type of treated cardiac arrhythmia. Historically, screening options for early AF detection have been limited. Pairing AliveCor’s KardiaMobile ECGs with BIOTRONIK’s implantable device data strives to streamline workflow by providing comprehensive visibility within a single solution.
Until now, remote personal monitoring data and implantable device data have rarely been integrated, making it difficult for healthcare providers to access the full range of patient data. “Our FDA-cleared ECG technology paired with BIOTRONIK’s implantable devices for cardiac rhythm diagnostics will allow a holistic view of the patient’s heart health on the go, while providing critical insights for physicians,” said Vincent Balsamo, Executive Vice President of Global Sales at AliveCor.
“Connecting wearable and implantable cardiac diagnostic device data from the earliest stages in the care continuum is groundbreaking,” said Kenneth Nelson, Head of Digital Health and Diagnostics at BIOTRONIK. “This pilot project intends to give physicians and caregivers a more longitudinal view of the patient’s condition while simultaneously reducing overall time spent on data management. We are proud to be on the frontier driving novel innovation.”
This partnership aims to enable faster diagnosis, more informed clinical decision-making and effective treatment by bringing complete information to every step in the diagnosis, device implant, and management process. Providing connected solutions with EHR-integrated monitoring may facilitate seamless sharing of secure ECG data to optimize physicians’ workflow. “BIOTRONIK is pioneering a digital health ecosystem that is long overdue in the cardiac device industry,” said Raul Weiss, MD, FHRS, FACC, Professor of Clinical Medicine, Cardiologist, Director, Electrophysiology Fellowship Program, Ohio State University Medical Center.
This pilot collaboration is the first in a series of partnerships with leading digital health organizations to improve the delivery of connected care in cardiac diagnostics and remote patient monitoring.
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more